The stock of Myriad Genetics, Inc. (MYGN) has gone down by -9.71% for the week, with a -14.31% drop in the past month and a -8.37% drop in the past quarter. The volatility ratio for the week is 4.11%, and the volatility levels for the past 30 days are 3.79% for MYGN. The simple moving average for the past 20 days is -10.46% for MYGN’s stock, with a -4.11% simple moving average for the past 200 days.
Is It Worth Investing in Myriad Genetics, Inc. (NASDAQ: MYGN) Right Now?
Additionally, the 36-month beta value for MYGN is 1.98. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 9 rating it as “hold,” and 3 rating it as “sell.”
The public float for MYGN is 86.02M and currently, short sellers hold a 6.59% ratio of that float. The average trading volume of MYGN on April 19, 2024 was 617.38K shares.
MYGN) stock’s latest price update
Myriad Genetics, Inc. (NASDAQ: MYGN)’s stock price has plunge by -0.70relation to previous closing price of 18.64. Nevertheless, the company has seen a -9.71% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-11 that Myriad Genetics’ (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
Analysts’ Opinion of MYGN
Many brokerage firms have already submitted their reports for MYGN stocks, with Piper Sandler repeating the rating for MYGN by listing it as a “Neutral.” The predicted price for MYGN in the upcoming period, according to Piper Sandler is $23 based on the research report published on December 21, 2023 of the previous year 2023.
Wells Fargo, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $20. The rating they have provided for MYGN stocks is “Equal Weight” according to the report published on December 19th, 2023.
Guggenheim gave a rating of “Buy” to MYGN, setting the target price at $23 in the report published on December 14th of the previous year.
MYGN Trading at -14.62% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.54% of loss for the given period.
Volatility was left at 3.79%, however, over the last 30 days, the volatility rate increased by 4.11%, as shares sank -16.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.59% lower at present.
During the last 5 trading sessions, MYGN fell by -9.71%, which changed the moving average for the period of 200-days by -20.28% in comparison to the 20-day moving average, which settled at $20.49. In addition, Myriad Genetics, Inc. saw -3.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from Riggsbee Richard Bryan, who sale 30,000 shares at the price of $19.09 back on Dec 01 ’23. After this action, Riggsbee Richard Bryan now owns 291,812 shares of Myriad Genetics, Inc., valued at $572,835 using the latest closing price.
Riggsbee Richard Bryan, the Chief Financial Officer of Myriad Genetics, Inc., sale 30,000 shares at $15.69 during a trade that took place back on Nov 01 ’23, which means that Riggsbee Richard Bryan is holding 321,812 shares at $470,622 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc. stands at -0.37. The total capital return value is set at -0.29. Equity return is now at value -31.55, with -20.54 for asset returns.
Based on Myriad Genetics, Inc. (MYGN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.32. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -93.79.
Currently, EBITDA for the company is -67.8 million with net debt to EBITDA at -0.59. When we switch over and look at the enterprise to sales, we see a ratio of 2.44. The receivables turnover for the company is 6.38for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.01.
Conclusion
In conclusion, Myriad Genetics, Inc. (MYGN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
